What Does Turning Point Therapeutics Do?

Total employees280
HeadquartersSan Diego
Founded2013

TP Therapeutics, Inc., which operated as Turning Point Therapeutics, was a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies. Their pipeline focused on addressing limitations of existing cancer therapies by targeting common oncogenic drivers of cancer with next-generation kinase inhibitors. A key asset was repotrectinib, a promising ROS1/TRK inhibitor. In August 2022, Turning Point Therapeutics was acquired by Bristol Myers Squibb (BMS) for $4.1 billion, integrating its innovative drug candidates and research platforms into BMS's oncology portfolio.

Where Is Turning Point Therapeutics's Headquarters?

Turning Point Therapeutics officeTurning Point Therapeutics officeTurning Point Therapeutics officeTurning Point Therapeutics office
*Images sourced via web search. Rights belong to original owners

HQ Function

Served as the primary center for research and development, clinical operations, corporate strategy, and administrative functions for its precision oncology programs.

Notable Features:

The headquarters was likely situated in a modern biotech park, equipped with advanced laboratory facilities for drug discovery and development, alongside collaborative office spaces designed to foster innovation.

Work Culture:

As a clinical-stage biotech, the work culture was likely dynamic, science-driven, and highly collaborative, with a strong sense of urgency and mission focused on developing impactful cancer treatments for patients.

HQ Significance:

The San Diego headquarters was crucial for leveraging the rich local biotech ecosystem, including access to talent, research institutions, and service providers, facilitating the advancement of its pipeline.

Values Reflected in HQ: The headquarters likely reflected values of innovation, scientific excellence, patient-centricity, and collaboration in its design and operations.

Location:

Prior to its acquisition, Turning Point Therapeutics' global presence was primarily defined by its international clinical trial activities for its oncology drug candidates. These trials often involved sites and investigators across North America, Europe, and Asia-Pacific. Direct operational office presence outside the United States was not significant, with global functions largely managed from their San Diego headquarters.

Street Address:

10628 Science Center Drive, Suite 200

City:

San Diego

State/Province:

California

Country:

USA

Where Else Does Turning Point Therapeutics Operate Around the World?

Information Scarcity

Address: Not Publicly Detailed

Any minor regional presence would have been to support core functions like clinical trial execution or specific collaborations, rather than fully independent office sites.

Buying Intent Signals for Turning Point Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Turning Point Therapeutics? Meet the Executive Team

As of April 2025, Turning Point Therapeutics' leadership includes:

Athena Countouriotis, M.D. - Former President and Chief Executive Officer
Paolo Tombesi - Former Executive Vice President and Chief Financial Officer
Mohammad Hirmand, M.D. - Former Executive Vice President and Chief Medical Officer
Siegfried Reich, Ph.D. - Former Executive Vice President and Chief Scientific Officer
Liang Schweizer, Ph.D. - Former Executive Vice President, Chief G&A and People Officer
Jim Mazzola - Former Executive Vice President, Chief Commercial Officer

Who's Investing in Turning Point Therapeutics?

Turning Point Therapeutics has been backed by several prominent investors over the years, including:

OrbiMed
Boxer Capital (Tavistock Group)
Foresite Capital
SR One
Lilly Asia Ventures
HBM Healthcare Investments
Nextech Invest
Partner Fund Management

What Leadership Changes Has Turning Point Therapeutics Seen Recently?

Hire0
Exits6

The most significant executive event was the acquisition by Bristol Myers Squibb in August 2022, which led to the transition of the entire executive team as an independent entity. Specific individual hires or exits in the 12 months leading up to this were less prominent than the overall change due to the acquisition.

Departures

Athena Countouriotis, M.D., Departed role following acquisition by Bristol Myers Squibb.
Paolo Tombesi, Departed role following acquisition by Bristol Myers Squibb.
Mohammad Hirmand, M.D., Departed role following acquisition by Bristol Myers Squibb.
Siegfried Reich, Ph.D., Departed role following acquisition by Bristol Myers Squibb.
Liang Schweizer, Ph.D., Departed role following acquisition by Bristol Myers Squibb.
Jim Mazzola, Departed role following acquisition by Bristol Myers Squibb.

What Technology (Tech Stack) Is Used byTurning Point Therapeutics?

Discover the tools Turning Point Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Turning Point Therapeutics Email Formats and Examples

Prior to its acquisition by Bristol Myers Squibb, Turning Point Therapeutics likely used a standard corporate email format such as first initial followed by last name, or first name.last name @tptherapeutics.com. These email addresses are no longer active.

[first_initial][last]@tptherapeutics.com or [first].[last]@tptherapeutics.com

Format

acountouriotis@tptherapeutics.com

Example

0%

Success rate

What's the Latest News About Turning Point Therapeutics?

Bristol Myers Squibb • August 16, 2022

Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Strengthening Precision Oncology Pipeline

Bristol Myers Squibb announced the successful completion of its acquisition of Turning Point Therapeutics, Inc. This acquisition brings repotrectinib, a next-generation kinase inhibitor, into BMS's oncology portfolio....more

Bristol Myers Squibb • June 3, 2022

Bristol Myers Squibb Strengthens Precision Oncology Pipeline with Acquisition of Turning Point Therapeutics

Bristol Myers Squibb (NYSE: BMY) and Turning Point Therapeutics, Inc. (NASDAQ: TPTX) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point Therapeutics for $76.00 per share in an all-cash transaction, for a total of $4.1 billion....more

PR Newswire (via Turning Point Therapeutics) • September 16, 2021

Turning Point Therapeutics Announces Positive Topline Data from Registrational TRIDENT-1 Study of Repotrectinib in ROS1-Positive Advanced NSCLC Patients

Turning Point Therapeutics announced positive topline data from the registrational TRIDENT-1 study of repotrectinib, its lead drug candidate, in patients with ROS1-positive advanced non-small cell lung cancer (NSCLC). The data highlighted strong efficacy and durability....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Turning Point Therapeutics, are just a search away.